# EraCal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eracal-therapeutics

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.eracal.ch
- Total disclosed funding: $1M
- Latest round: Seed (Oct 16, 2019)
- Investors on record: 5

## About

EraCal Therapeutics Ltd. is a Swiss company specializing in innovative solutions for obesity management, focusing on advanced therapeutic products that enhance metabolic health and facilitate effective weight management.Founded in Zurich, Switzerland in 2018 by Josua Jordi, EraCal Therapeutics Ltd. is dedicated to developing therapeutic interventions for weight management. The company has engaged in two notable deals, with its most recent funding round being a Seed round in October 2019 that raised CHF 1.000 mn, led by Life Sciences Fund Amsterdam alongside other investors including Novartis Venture Fund and UZH Life Sciences Fund.EraCal Therapeutics specializes in innovative solutions aimed at combating obesity through a suite of scientifically developed products. The company's primary offerings focus on advanced therapeutic interventions that target metabolic health and weight management, leveraging cutting-edge research and technology to address both physiological and psychological factors contributing to obesity. EraCal Therapeutics serves a diverse client base, including healthcare providers, wellness centers, and directly to consumers seeking effective weight management solutions, with products distributed across key markets in North America and Europe.EraCal Therapeutics generates revenue through a structured business model that includes direct-to-consumer sales and partnerships with healthcare providers and wellness organizations. The company capitalizes on subscription-based services for its flagship products, ensuring ongoing access to therapeutic solutions and support. By establishing relationships with retailers and wholesalers, EraCal Therapeutics guarantees broader availability of its products, with pricing reflecting the innovative science behind them.EraCal Therapeutics Ltd. plans to leverage its recent Seed funding, raised in October 2019, to enhance product development and expand its market reach. The company is focused on launching new therapeutic products aimed at improving metabolic health, with plans for introduction in 2022. Additionally, EraCal aims to penetrate new markets in Asia and South America by 2023, responding to the increasing global demand for effective obesity management solutions.

## Funding rounds

- Seed, Oct 16, 2019 — Redalpine, UZH Life Sciences Fund, Bernina BioInvest AG
- Seed, Jun 4, 2019, $1M — Novartis Venture Fund, Life Sciences Fund Amsterdam, UZH Life Sciences Fund

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed
- Life Sciences Fund Amsterdam (https://capitalatlas.ai/funds/life-sciences-fund-amsterdam) — Seed
- UZH Life Sciences Fund — Seed
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Seed
- Bernina BioInvest AG — Seed